Sygnature Discovery is a contract research organisation that is driven by helping our customers create life-changing medicines for those most in need around the globe. The value of animals in this mission is vital for understanding these compounds and their effect on the body, and producing safe and effective treatments for the world’s worst diseases. Without animal research, we would not be able to create the life-changing therapeutics that are so desperately needed.
Animal welfare is our top priority at Sygnature Discovery. We employ the highest standards of animal care and implement the principles of the 3Rs (replacement, reduction and refinement) to all studies, and have worked hard to foster a culture of compassion and care towards all our animals. Our statisticians ensure the use of optimal experimental design in order to carry out studies with the fewest number of animals possible, and we take great care to minimise any pain or distress before, during, and after experimental procedures.
The welfare of animals used in novel pharmaceutical research is of critical importance. We believe that appropriate housing, trained staff and the use of refined methods are essential not only in ensuring a high standard of animal care and welfare, but also the generation of robust and reproducible data.
The use of animals in research is regulated by the Animals (Scientific Procedures) Act 1986 (amended in 2012). These regulations extend the European Directive 2010/63/EU, which sets out measures for the protection of animals used for scientific purposes. All in vivo studies at Sygnature Disocvery are conducted in state-of-the–art-facilities with veterinary care by our professional, fully trained staff, in complete compliance with relevant legislation and internationally-accepted guidelines.